

## REVIEW

# Overview of the Publications From the Anthroposophic Medicine Outcomes Study (AMOS): A Whole System Evaluation Study

人智医学结果研究 (AMOS) 出版物概述: 全系统评价研究

Descripción general de las publicaciones del estudio de los resultados de la medicina antroposófica (AMOS): Estudio de evaluación del sistema completo

Harald Johan Hamre, Dr med, *Germany*; Helmut Kiene, Dr med, *Germany*; Renatus Ziegler, Dr rer nat, *Switzerland*; Wilfried Tröger, Dr rer nat, *Germany*; Christoph Meinecke, Dr med, *Germany*; Christof Schnürer, Dr med, *Germany*; Hendrik Vögler, Dr med, *Germany*; Anja Glockmann, Dipl Biol, *Germany*; Gunver Sophia Kienle, Dr med, *Germany*

## ABSTRACT

Anthroposophic medicine is a physician-provided complementary therapy system that was founded by Rudolf Steiner and Ita Wegman. Anthroposophic therapy includes special medicinal products, artistic therapies, eurythmy movement exercises, and special physical therapies. The Anthroposophic Medicine Outcomes Study (AMOS) was a prospective observational multicenter study of 1631 outpatients starting anthroposophic therapy for anxiety disorders, asthma, attention deficit hyperactivity disorder, depression, low back pain, migraine, and other chronic indications under routine conditions in Germany.

AMOS incorporated two features proposed for the evaluation of integrative therapy systems: (1) a sequential approach, starting with the whole therapy system (use, safety, outcomes, perceived benefit), addressing comparative effectiveness and proceeding to the major system components (physician counseling, anthroposophic medicinal products, art therapy, eurythmy therapy, rhythmical massage therapy) and (2) a mix of different research methods to build an information synthesis, including pre-post analyses, prospective comparative analyses, economic analyses, and safety analyses of individual patient data.

AMOS fostered two methodological innovations for the analysis of single-arm therapy studies (combined bias suppression, systematic outcome comparison with corresponding cohorts in other studies) and the first depression cost analysis worldwide comparing primary care patients treated for depression vs depressed patients treated for another disorder vs nondepressed patients.

A total of 21 peer-reviewed publications from AMOS have resulted. This article provides an overview of the main research questions, methods, and findings from these publications: anthroposophic treatment was safe and was associated with clinically relevant improvements in symptoms and quality of life without cost increase; improvements were found in all age, diagnosis, and therapy modality groups and were retained at 48-month follow-up; nonrespondent bias, natural recovery, regression to the mean, and adjunctive therapies together could explain a maximum of 37% of the improvement.

## 摘要

人智医学是一个由 Rudolf Steiner 和 Ita Wegman 建立、由医生提供的补充治疗系统。人智治疗包括特殊医药产品、艺术疗法、音语舞运动锻炼和特殊物理疗法。人智医学结果研究 (AMOS) 是一项预期的、

多中心观察研究, 参与者为 1631 名德国门诊患者, 他们因焦虑症、哮喘、注意缺陷多动障碍、抑郁症、腰疼、偏头痛和其他常见疾病的慢性迹象而开始接受人智治疗。AMOS 整合了拟定用于评价综合性治疗系统的两项特征: (1) 采用顺序的方法, 从整个治疗系统开始 (使用、安全性、结果、感知益处), 到比较疗效, 再到重要系统组件 (医生咨询、人智医药产品、艺术疗法、音语舞疗法、节律性按摩疗法), 并 (2) 融合了不同的研究方法, 建立了一个信息综合体, 包括对单个患者数据进行治疗前后分析、预期比较分析、经济分析和安全性分析。AMOS 促进了单组治疗研究分析方面的两项方法学创新 (组合式偏差避免, 与其他研究中相应人群进行的系统性结果比较), 并且首次在全世界范围内进行了抑郁症成本分析, 即对接受抑郁症治疗的基础护理患者、就另一项疾病接受治疗的抑郁症患者和非抑郁症患者进行了比较。AMOS 共发表了 21 个经同行评审的出版物。本文概述了这些出版物的主要研究问题、方法和发现结果: 人智治疗非常安全, 可在不增加费用的情况下在症状和生活质量方面产生临床相关改善; 这种改善见于所有年龄、诊断和治疗模式小组的人群之中, 并且保持 48 个月的跟进期; 存在无应答偏差、自然恢复、趋均数回归和附加治疗这些现象, 因而至多改善 37%。

## Funding

The AMOS and subsequent publications were funded by the Innungskrankenkasse Hamburg (now IKK Classic) and the Software-AG Stiftung with supplementary grants from the Deutsche BKK, The Betriebskrankenkasse des Bundesverkehrsministeriums, the Christophorus-Stiftungsfonds in der GLS Treuhand e. V., the Förderstiftung Anthroposophische Medizin, the Dr Hauschka Stiftung, the Helixor Stiftung, the Mahle Stiftung, Wala-Heilmittel GmbH, and Weleda AG. The sponsors had no influence on design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

**Author Affiliations**  
Institute for Applied Epistemology and Medical Methodology at the University of Witten-Herdecke, Freiburg, Germany (Drs Hamre, Kienle, Kiene, and Ms Glockmann); Institute Hiscia, Society for Cancer Research, Arlesheim, Switzerland (Dr Ziegler); Clinical Research Dr Tröger, Freiburg (Dr Tröger); Community Hospital Havelhöhe, Berlin, Germany (Dr Meinecke); Albert-Fraenkel-Centrum, Badenweiler, Germany (Dr Schnürer); Ita Wegman Therapeutikum, Dortmund, Germany (Dr Vögler). Dr Vögler was the contact person for the Anthroposophic Medicine Outcomes Study (AMOS) in the Physicians' Association for Anthroposophical Medicine in Germany.

## Correspondence

Harald Johan Hamre, Dr med  
harald.hamre@ifaeamm.de

## Citation

Global Adv Health Med. 2014;3(1):54-70. DOI: 10.7453/gahmj.2013.010

## Key Words

Anthroposophic medicine, eurythmy therapy, art therapy, rhythmical massage therapy, drug therapy, observational studies, whole system evaluation, review

## Disclosures

The authors completed the ICMJE Form for Potential Conflicts of Interest and had no relevant conflicts to disclose.

## SINOPSIS

La medicina antroposófica es un sistema terapéutico complementario proporcionado por el médico que fue fundada por Rudolf Steiner e Ita Wegman. La terapia antroposófica incluye productos medicinales especiales, terapias artísticas, ejercicios de movimiento eurítmico y terapias físicas especiales. El estudio de los resultados de la medicina antroposófica (Anthroposophic Medicine Outcomes Study, AMOS) consistió en un estudio prospectivo observacional multicéntrico de 1631 pacientes ambulatorios que comenzaban la terapia antroposófica para trastornos de ansiedad, asma, trastorno de hiperactividad y déficit de atención, depresión, dolor lumbar, migraña y otras indicaciones crónicas bajo condiciones rutinarias en Alemania.

AMOS incorporaba dos características propuestas para la evaluación de sistemas terapéuticos inte-

grales: (1) un enfoque secuencial, comenzando con el sistema terapéutico completo (uso, seguridad, resultados, ventaja percibida), que aborda la eficacia comparativa y continúa con los componentes principales del sistema (asesoramiento del médico, productos medicinales antroposóficos, terapia artística, terapia eurítmica, terapia de masaje rítmico) y (2) una combinación de diferentes métodos de investigación para crear una síntesis de información, que incluye análisis previos y posteriores, análisis comparativos prospectivos, análisis económicos y análisis de la seguridad de los datos del paciente individual. AMOS fomentaba dos innovaciones metodológicas para el análisis de los estudios terapéuticos de un grupo único (supresión del sesgo combinado, comparación sistemática de resultados con las cohortes correspondientes en otros estudios) y el primer análisis a nivel

mundial del coste de la depresión comparando pacientes de atención primaria tratados de depresión frente a pacientes deprimidos tratados por otro trastorno frente a pacientes no deprimidos.

Ha resultado en un total de 21 publicaciones revisadas por expertos de AMOS. Este artículo proporciona una visión general de las principales cuestiones de investigación, métodos y los resultados de estas publicaciones: el tratamiento antroposófico era seguro y se asociaba a mejoras clínicamente relevantes en los síntomas y la calidad de vida sin aumento de los costes; se observaron mejoras en todos los grupos de edad, diagnóstico y modalidad de terapia y se mantuvieron en el seguimiento de 48 meses; el sesgo ajeno a los entrevistados, la recuperación natural, la regresión a la media y las terapias adyuvantes juntos podían explicar un máximo del 37 % de la mejora.

## BACKGROUND

### Anthroposophic Medicine

Anthroposophic medicine (AM) is a physician-provided whole therapy system, founded in Central Europe the 1920s by Rudolf Steiner and Ita Wegman.<sup>1,2</sup> In AM, the methods and insights of conventional medicine are extended by the methods and insights of anthroposophy. Anthroposophy (Greek: *anthropos* = man; *sophia* = wisdom) was established by Rudolf Steiner<sup>3</sup> and is founded in three Western traditions: the empirical tradition in the natural sciences from the 17th century onward; the cognitional tradition in philosophy (starting with Plato and Aristotle and culminating in the German idealism of the 19th century); and the esoteric tradition in Christian spirituality. Anthroposophy represents a view of man and nature that is spiritual and that also claims to be profoundly scientific.<sup>4</sup>

According to anthroposophy, the human organism is formed by not only physical (cellular, molecular) forces but by four classes of formative forces, three of which are also found in nature: (1) in minerals, *material* forces of physicochemical matter; (2) in plants, formative *vegetative* forces interact with material forces, bringing about and maintaining the living form; (3) in animals with sensory and motor systems and with a corresponding inner life, a further class of formative forces (*anima*, soul) interact with material and vegetative forces; (4) in the human organism with its individual mind and capacity of thinking, another class of formative forces (*Geist*, spirit) interact with the material, vegetative, and soul forces. The interactions of these

forces are understood to vary between different regions and organs in the human organism, resulting in a complex equilibrium. This equilibrium can be distorted in various forms of human disease and is sought to be regulated by AM therapies.<sup>4,5</sup>

AM therapies include special anthroposophic medicinal products (AMPs), nonverbal artistic therapies, eurythmy movement exercises, special physiotherapy modalities such as rhythmical massage therapy, and special nursing techniques.<sup>1,4</sup> These therapies are provided by licensed physicians, nurses, physiotherapists, and other qualified nonmedical therapists (AM art and eurythmy therapy).<sup>6</sup>

AMPs are prepared from plants, minerals, animals, and chemically defined substances. Similar to homeopathic products, AMPs can be prepared in homeopathic potencies,<sup>a</sup> but many AMPs are prepared in concentrated form.<sup>7</sup> AMP therapy differs from homeopathy in other aspects as well:

- The rationale for AMP therapy is based on typological correspondences between pathophysiological processes in man and formative forces working in minerals, plants, and animals (see above),<sup>4</sup> while the *simile* principle of homeopathy is based on symptom correspondences<sup>8</sup>;

<sup>a</sup> All homeopathic products and many AMPs are "potentized," ie, successively diluted, each dilution step involving a rhythmic succussion (repeated shaking of liquids) or trituration (grinding of solids into lactose monohydrate). A D30 potency (also called 30X) has been potentized in a 1:10 dilution for 30 times, resulting in a 1:10<sup>30</sup> dilution.

- the manufacturing of AMPs includes special pharmaceutical processes that are rarely used for homeopathic or other non-AM products: eg, production of metal mirrors by chemical vapor decomposition and processing of herbs by fermentation, toasting, carbonization, incineration, or digestion (heat treatment at 37°C);<sup>7</sup> and
- potentized AMPs are rarely prepared in potencies higher than D30.<sup>9</sup>

In AM art therapy, the patients engage in painting, drawing, sculpture modeling, or music or speech exercises, whereby the specific qualities of each artistic medium are utilized to achieve specific effects.<sup>10-15</sup>

Eurythmy therapy is an artistic exercise therapy involving cognitive, emotional, and volitional elements. In eurythmy therapy sessions, patients exercise specific movements with the hands, the feet, or the whole body. Eurythmy movements are related to the sounds of vowels and consonants, to music intervals, or to soul gestures (eg, sympathy-antipathy). Between therapy sessions, the patients exercise eurythmy movements daily.<sup>16,17</sup>

Rhythmical massage therapy was developed from Swedish massage. In rhythmical massage treatment, traditional massage techniques (effleurage, petrissage, friction, tapotement, vibration) are supplemented by special techniques such as gentle lifting movements, rhythmically undulating gliding movements, and complex movement patterns like lemniscates.<sup>18,19</sup>

AM training programs for physicians and therapists are offered at university medical schools or high schools or as separate programs. The programs follow international, standardized curricula and lead to national or international certification as “AM physician,” “AM art therapist,” etc.<sup>6</sup> Therapy guidelines exist for AM medical therapy,<sup>20</sup> AM art therapy,<sup>21</sup> and eurythmy therapy.<sup>22</sup>

Before prescribing AMPs or referring patients for AM therapies, AM physicians have prolonged consultations with the patients and their caregivers. These consultations are used to take an extended history, to address constitutional and psychosocial aspect of the patients’ illness, to explore the patients’ and caregivers’ preparedness to engage in treatment, and to select optimal, individualized therapy for each patient.<sup>1,19</sup> In addition to individualized therapy, a number of standardized AMP treatment regimens involving one or several pre-defined AMPs are available.<sup>23</sup>

To a certain extent, patients also can start AM therapy independently of a physician, as some AMPs are available without prescription and as patients can go directly to AM therapists.

Currently, AM is practiced in 66 countries worldwide, with the majority of AM physicians working in Europe (Germany, Switzerland, France, Poland, Italy, Spain, The Netherlands) and the Americas (Argentina, United States, Brazil).<sup>6</sup> AM is used for the whole spectrum of diseases and is integrated into the whole range of healthcare provision. Thus, in Europe, AM is prac-

ticed in 24 inpatient hospitals, 14 of which are hospitals with trauma and emergency services, including two university teaching hospitals and one hospital providing emergency services for a large German airport.<sup>6</sup> In the United Kingdom, the National Centre for Social Research has studied AM as a possible model of integrated primary care.<sup>19</sup> In Germany, AM is recognized, alongside homeopathy and phytotherapy, as “particular therapy system” under the Medicines Act and is represented by its own committee at the Federal Institute for Drugs and Medical Devices.<sup>24</sup> Reimbursement of AM treatment costs by health insurance systems differs across countries and is, inverse to the higher concentration of AM practitioners in Europe, more widespread outside Europe than in Europe.<sup>6</sup>

### The Anthroposophic Medicine Outcomes Study

The Anthroposophic Medicine Outcomes Study (AMOS) was occasioned by a health benefit program in Germany. The program included reimbursement of AM treatment costs in outpatients in those two areas:

- medical therapy: prolonged consultation with AM physicians; and
- nonmedical therapy on prescription from AM physicians: AM art therapy, eurythmy therapy, and rhythmical massage therapy.

AMOS was a prospective 4-year observational study of patients starting AM outpatient treatment under routine conditions. Eligibility criteria followed the criteria for inclusion in the health benefit program: adults and children with any chronic condition.<sup>25</sup>

Patients were enrolled in AMOS between the years 1998 and 2005. When 2-year findings in patients enrolled up to March 2001 were first published,<sup>25</sup> there was still a scarcity of published data on use, effectiveness, long-term outcomes, safety, and costs of AM treatment in outpatient care—in general and in patient subgroups according to age, diagnosis, and AM therapy modalities. Much detailed information on these topics became available from AMOS, and the following study analyses were published separately: clinical outcomes in all patients after 4 years,<sup>26</sup> in children,<sup>27</sup> in the six largest diagnosis groups,<sup>28-33</sup> and in the four major therapy modality groups<sup>34-37</sup>; a nested prospective comparison to conventional treatment for low back pain<sup>38</sup>; a health costs analysis<sup>39</sup>; and a safety analysis of AMPs.<sup>40</sup> All 16 of these analyses<sup>25-40</sup> were pre-planned (eg, a 4-year follow-up had been implemented on all patients enrolled from 1999 to 2005; specific documentation modules had been implemented for children and for 10 diagnoses, six of which had at least 40 patients each enrolled in AMOS and were published separately). In addition, five secondary analyses (outcomes in patients using AMPs,<sup>41</sup> outcome predictors in adults,<sup>42</sup> impact of depression and depressive symptoms on health costs in adults,<sup>43</sup> systematic outcome comparison with corresponding cohorts in other studies,<sup>44</sup> combined bias sup-

**Table 1** Overview of Publications From the Anthroposophic Medicine Outcomes Study (AMOS)

Clinical outcomes	Reference no.	
All patients	Primary analysis	25
	Follow-up analysis after 48 months	26
Children		27
Diagnosis groups	Anxiety disorders	28
	Asthma	29
	Attention deficit/hyperactivity disorder symptoms	30
	Depression	31
	Low back pain	
	-Comparison to conventional therapy after 12 mo	38
	-Follow-up analysis after 24 mo	32
	Migraine	33
Therapy groups	Medical treatment	
	-Prolonged consultations with anthroposophic physicians	34
	-Anthroposophic medicinal products	41
	Art therapy	35
	Eurythmy therapy	36
	Rhythmical massage therapy	37
Supplementary analyses	Outcome predictors in adults	42
	Systematic outcome comparison with corresponding cohorts in other studies	44
	Combined bias suppression	45
Costs	All age groups	39
	Adults: depression vs depressive symptoms vs no depressive symptoms	43
Medication safety		40

pression analysis of clinical outcomes<sup>45</sup>) were published, resulting in a total of 21 peer-review publications<sup>25-45</sup> (Table 1). This article provides an overview of the main research questions, methods, and findings from these publications.

**METHODS**

**Study Design and Objectives**

AMOS was a prospective observational cohort study in a real-world medical setting. The study was initiated by a health insurance company in conjunction with a health benefit program.<sup>46</sup> The main objectives were to study clinical outcomes following AM treatment as well as safety and health costs. Further research questions concerned characteristics of AM users, AM therapy administration, use of non-AM adjunctive therapies, and patient satisfaction.

**Setting, Participants, and Therapy**

All physicians certified by the Physicians'

Association for Anthroposophical Medicine in Germany and working in an office-based practice or outpatient clinic were invited to participate in the AMOS study. In the period from July 1, 1998, to December 31, 2005, a total of 151 participating physicians recruited 1631 consecutive patients starting AM therapy under routine clinical conditions. Inclusion criteria for all analyses were the following:

1. Outpatients aged 1 to 75 years and living in Germany; and
2. starting AM therapy for a chronic indication (main disorder)
  - 2a) AM-related consultation of at least 30 minutes followed by new prescription of at least one AMP or
  - 2b) referral to AM therapy by nonmedical therapist: art, eurythmy, or rhythmical massage.

Patients were excluded if they had previously received the AM therapy in question (see inclusion criteria no. 2) for their main diagnosis. Further eligibility criteria applied to individual analyses, eg, a minimum disease duration of 30 days,<sup>26-28,41,42</sup> 6 weeks,<sup>32,38</sup> or 6 months<sup>30,31,43</sup> or further age restrictions (Table 2). Inclusion criteria for the analysis of major diagnosis groups were the following:

- anxiety disorder<sup>28</sup>: physician's diagnosis (International Classification of Diseases, 10th edition [ICD-10] F40-F42 or F43.1),
- asthma<sup>29</sup>: physician's diagnosis (ICD-10 J45);
- attention deficit/hyperactivity disorder (ADHD) symptoms<sup>30</sup>: physician's diagnosis (ICD-10 F90);
- depression<sup>31</sup>: adapted criteria for dysthymic disorder from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)<sup>47</sup>;
- low back pain<sup>32,38</sup>: physician's diagnosis (ICD-10 M40-54); and
- migraine<sup>33</sup>: criteria of the International Headache Society.<sup>48</sup>

For the diagnosis group low back pain, additional exclusion criteria were previous back surgery and 11 specific diagnoses.<sup>32,38</sup> Other inclusion criteria were for a safety analysis of AMPs, the use of at least one AMP,<sup>40</sup> and for three analyses, the availability of follow-up data.<sup>38,39,42</sup>

AM therapy was administrated at the discretion of the physicians and therapists and evaluated as a whole system<sup>49</sup> with subgroup analyses of age, diagnosis, and therapy modality groups. In the latter analyses, patients fulfilling inclusion criteria 2a as well as 2b (see above) were analyzed in group 2b,<sup>34-37</sup> except in an analysis of AMP use.<sup>41</sup>

**MAJOR OUTCOME MEASURES**

**Clinical Outcomes and Patient Satisfaction**

For analyses of clinical outcome across indications



**Table 2** Overview of Main Results From the Anthroposophic Medicine Outcomes Study Publications

Diagnosis	Therapy	N enrolled	Recruitment	Age, y	Month	Primary follow-up assessment	Outcome measure <sup>a</sup> , improvement Evaluable from baseline (95% confidence interval), patients P value	Last follow-up	Reference no.
								Mo	
All	AM	898	Jul 1998- Mar 2001	1-75	6	92%	Symptom Score: median 2.67 (2.50-2.83), P<.001	24	25
							Disease Score: median 3.50 (3.00-3.50), P<.001		25
All	AM	1510	Jan 1999- Dec 2005	1-75	48	61% <sup>b</sup>	Symptom Score: mean 2.83 (2.71-2.96), P<.001	48	26
All	AM	435	Jan 1999- Dec 2005	1-16	6	88%	Symptom Score: mean 2.41 (2.16-2.66), P<.001	24	27
							Disease Score: mean 3.00 (2.76-3.24), P<.001		27
Anxiety disorders	AM	64	Jan 1999- Dec 2005	17-75	6	78%	Anxiety Severity, patient rating: mean 3.50 (2.88-4.12), P<.001	24	28
							Anxiety Severity, physician rating: mean 3.60 (2.97-4.22), P<.001		28
Asthma	AM	90	Jan 1999- Dec 2005	2-70	12	74%	Average Asthma Severity: mean 2.61 (1.90-3.32), P<.001	24	29
ADHD symptoms	AM	61	Apr 2001- Dec 2005	3-16	6	77% <sup>a</sup>	FBB-HKS total score (range 0-3): mean 0.30 (0.18-0.43), P<.001	24	30
Depression	AM	97	Jul 1998- Mar 2001	17-70	12	85%	Center for Epidemiological Studies Depression Scale (range 0-60) <sup>77</sup> : median 15.5 (12.5-18.5), P<.001	48	31
Migraine	AM	45	Jan 1999- Dec 2005	17-75	6	76% <sup>a</sup>	Average Migraine Severity, patient rating: mean 2.84 (2.05-3.64), P<.001	24	33
							Average Migraine Severity, physician rating: mean 3.14 (2.40-3.87), P<.001		33
Low back pain	AM vs conventional	38 + 48	Jul 1998- Sep 2000	17-75	12	89% + 58%	More improvement in AM group for SF-36 Mental Health (P=.045), SF-36 General Health (P=.006), SF-36 Vitality (P=.005). No significant differences for improvements (AM vs conventional) in HFAQ, LBPRS, and other SF-36 scores.	12	38
Low back pain	AM	75	Jan 1999- Dec 2005	17-75	24	67%	HFAQ (range 0-100): mean 11.1 (5.5-16.6), P<.001	24	32
							LBPRS (range 0-100): mean 8.7 (4.4-13.0), P<.001		32
All	Prolonged consultation with AM physician	233	Jul 1998- Mar 2001	1-74	12	90%	Symptom Score: median 2.97 (2.50-3.25), P<.001	48	34
							Disease Score: median 4.00 (3.50-4.50), P<.001		34
All	AMPs	665	Jan 1999- Dec 2005	1-75	6	85%	Symptom Score: mean 2.43 (2.23-2.63), P<.001	12	41
							Disease Score: mean 3.15 (2.97-3.34), P<.001		41
All	Art therapy	161	Jul 1998- Mar 2001	5-71	12	88%	Symptom Score: median 2.67 (2.25-3.17), P<.001	48	35
							Disease Score: median 4.50 (4.00-5.00), P<.001		35
All	Eurythmy	419	Jul 1998- Mar 2001	1-75	12	88%	Symptom Score: median 2.50 (2.25-2.75), P<.001	48	36
							Disease Score: median 4.00 (3.50-4.00), P<.001		36

Table 2 continued on the next page.

**Table 2** Overview of Main Results From the Anthroposophic Medicine Outcomes Study Publications (cont.)

Diagnosis	Therapy	N enrolled	Recruitment	Age, y	Primary follow-up assessment			Last follow-up Mo	Reference no.
					Month	Outcome measure, improvement Evaluable from baseline (95% confidence interval), patients	P value		
All	Rhythmical massage	85	Jul 1998-Mar 2001	1-75	12	85%	Symptom Score: mean 2.63 (2.02-3.23), <i>P</i> <.001 Disease Score: mean 3.54 (2.88-4.19), <i>P</i> <.001	48	37
All	AM	1069 <sup>a</sup>	Jan 1999-Dec 2005	17-75	6	85%	Predictors of Symptom Score improvement after 6 and 12 months: baseline symptom severity + SF-36 physical function + SF-36 general health, disease duration	12	42
All	AM	887	Jul 1998-Mar 2001	1-75	6	83%	Disease Score without bias suppression: mean 2.97 (2.79-3.14), <i>P</i> <.001; Disease Score after suppression of non-respondent bias, natural recovery, adjunctive therapies, and regression to the mean: mean 1.87 (1.69-2.06), <i>P</i> <.001	6	45
Asthma, depression, low back pain, migraine, neck pain	AM vs conventional	392 + 16167	Jul 1998-Dec 2005	17-75	3 + 6 + 12	83% + 79%	Improvements in SF-36 scores in AMOS and comparison cohorts of similar magnitude (difference <0.50 SD) in 80.1% (414/517) of comparisons, differences ≥0.50 SD favoring AMOS and comparison cohorts, respectively, in 13.5% and 6.4%, respectively.	12	44
All	AMPs	662 <sup>c</sup>	Jan 1999-Mar 2001	1-75	24	97% <sup>c</sup>	Confirmed adverse drug reactions: 2.2% (21/949) of AMPs, 3.0% (20/662) of users, 0.3% (30/11487) of patient-months with AMP use	24	40
All	AM	717 <sup>d</sup>	Jan 1999-Mar 2001	1-75	12 + 24	88% <sup>d</sup>	Total health costs: bootstrap mean €3186 (95% confidence interval 3037-3711) in the pre-study year, €3297 (3157-3923) in the first year, €2771 (2647-3256) in the second year. In the second year, costs were reduced by €416 (264-960) from the pre-study year.	24	39
Groups 1-3 <sup>e</sup>	AM	487	Jan 1999-Mar 2001	17-70	12 + 24	85% <sup>a</sup>	Total health costs in the Groups 1-3 <sup>e</sup> averaged €7129, €4371, and €3532 in the pre-study year ( <i>P</i> =.008); €6029, €3522, and €3353 in the first year ( <i>P</i> =.083); and €4929, €3792, and €4031 in the second year ( <i>P</i> =.460). In the second year, costs in Group 1 were reduced by €1808 (1110-4858) from the pre-study year.	24	43

<sup>a</sup> Scores of clinical outcome measures are numerical rating scales (0-10) unless otherwise stated.  
<sup>b</sup> Analysis after replacement of missing values with last value carried forward, hence all patients with available baseline data (99%) were evaluable for analysis.  
<sup>c</sup> The analysis comprised patients with ≥1 of 5 follow-ups available (97%) and using AMPs, n = 662.  
<sup>d</sup> The analysis comprised patients with ≥3 of 5 follow-ups available, n = 717/811.  
<sup>e</sup> Group 1: patients treated for depression, Groups 2 and 3: patients treated for another disorder, with (Group 2) or without (Group 3) coexisting depressive symptoms.

Abbreviations: ADHD, attention deficit/hyperactivity disorder; AM, anthroposophic therapy (art, eurhythm, rhythmical massage, prolonged physician consultations, AMPs); AMPs, anthroposophic medicinal products; FBB-HKS: [German] Fremdbeurteilungsbogen für Hyperkinetische Störungen, a questionnaire of core ADHD symptoms; HFAQ, Hanover Functional Ability Questionnaire; LBPRS, Low Back Pain Rating Scale Pain Score; SF-36: Short Form (36) Health Survey; SRM, Standardized response mean effect size (minimal: <0.20, small: 0.20-0.49, medium: 0.50-0.79, large: ≥0.80).

the primary outcome was disease severity, assessed on numerical rating scales (NRS)<sup>50</sup> from 0 (“not present”) to 10 (“worst possible”): disease score (physicians’ global assessment of severity of main diagnosis); symptom score (patients’ assessment of severity of one to six most relevant symptoms present at baseline). For diagnosis-specific analyses, all primary outcomes were diagnosis-specific (Table 3). Other major clinical outcomes were quality of life (Table 4) and patient satisfaction.

Disease score was documented after 0, 6, and (for patients enrolled up to March 2001) 12 months; all other clinical outcomes after 0, 3, 6, 12, 18, 24, and (except quality of life in children) 48 months. The primary follow-up assessment of clinical outcomes was after 6 months<sup>25,27,28,30,33,41</sup> or 12 months,<sup>29,31,34,38</sup> while follow-up analyses were performed after 12 months,<sup>41</sup> 24 months,<sup>27-30,32,33</sup> or 48 months.<sup>26,34-37</sup> Patients’ therapy outcome ratings and patient satisfac-

**Table 3** Disease-specific Clinical Outcome Measures

Diagnosis group	Outcome measure	Rated by	Score range <sup>a</sup>	Properties	Reference no.
Anxiety disorders	Anxiety Severity	Patient	0-10	One NRS: 0 ("not present") to 10 ("worst possible")	50
		Physician	0-10	One NRS: 0 ("not present") to 10 ("worst possible")	50
Asthma	Average Asthma Severity	Patient or caregiver	0-10	One NRS: 0 ("not present") to 10 ("worst possible")	50
ADHD symptoms	FBB-HKS total score	Caregiver	0-3	20 items addressing inattention (9 items), hyperactivity (7 items), and impulsivity (7 items), assessed on Likert scales from 0 ("not present") to 3 ("very strong intensity")	51, 52
Depression	CES-D	Patient	0-60	Frequency of 20 symptoms during the last week, assessed on Likert scales from 0 ("rarely or none of the time ≈ less than 1 day") to 3 ("most or all of the time ≈ 5-7 days")	53
Migraine	Average Migraine Severity	Patient	0-10	One NRS: 0 ("not present") to 10 ("worst possible")	50
		Physician	0-10	One NRS: 0 ("not present") to 10 ("worst possible")	50
Low back pain	Hanover Functional Ability Questionnaire	Patient	0 (minimal function) to 100 (optimal function, no limitation)	Back-specific functional disability measured by 12 activity-related questions (eg, "Can you bend down to pick up a paper from the floor?"), assessed on three-point Likert scales ("Can do without difficulty" / "Can do, but with some difficulty" / "Either unable to do, or only with help")	54, 55
Low back pain	Low Back Pain Rating Scale Pain Score	Patient	0-100	6 items addressing back pain (3 items) and leg pain (3 items): current pain, worst pain, and average pain during the last 7 days on numerical rating scales from 0 ("no pain") to 100 ("unbearable pain")	56

<sup>a</sup> Higher score values indicate more frequent and/or worse symptoms unless otherwise stated.

Abbreviations: ADHD, attention deficit/hyperactivity disorder. CES-D, Center for Epidemiological Studies Depression Scale; FBB-HKS: [German] Fremdbeurteilungsbogen für Hyperkinetische Störungen, a questionnaire of core ADHD symptoms according to the *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition (DSM-IV) and *International Classification of Diseases*, 10th edition (ICD-10); NRS, numerical rating scale.

tion with therapy were documented after 6 and 12 months on NRS (0-10).

**Safety.** Suspected adverse reactions to medications or therapies were documented by the patients after 6, 12, 18, and 24 months and by the physicians after 6 months (for patients enrolled before April 1, 2001, also after 3, 9, and 12 months). The documentation included suspected cause, intensity (mild/moderate/severe), and therapy withdrawal because of adverse reactions. Serious adverse events were documented by the physicians throughout the study months 0 to 24.

**Health Costs.** Outcome of cost analyses<sup>25,39,43</sup> was health costs, regardless of diagnosis, in the pre-study year and in the first and (not in<sup>25</sup>) second study years. All analyses comprised direct health costs for AM therapies and AMPs, physician and dentist visits, psychotherapy, non-AM medication, physiotherapy, occupational therapy, and inpatient hospital and rehabilitation treatment as well as indirect costs for sick leave compensation. One analysis<sup>43</sup> comprised further direct (non-AM complementary therapies) and indirect (early retirement, mortality) costs.

#### Data Collection

All data were documented with questionnaires returned in sealed envelopes to the study office. The physicians documented eligibility criteria, disease score, anxiety severity, migraine severity (Table 3), and safety data (see above); the therapists documented AM

therapy administration; all other items were documented by the patients or caregivers unless otherwise stated. The patient responses were not made available to the physicians. The physicians were compensated 40 Euro (after March 2001: 60 Euro) per included and fully documented patient, while the patients and their caregivers received no compensation. The data were entered twice by two different persons into Microsoft Access 97 (Microsoft Corp, Redmond, Washington). The two datasets were compared and discrepancies resolved by checking with the original data.

#### Quality Assurance and Adherence to Regulations and Reporting Guidelines

The study was approved by the Ethics Committee of the Faculty of Medicine Charité, Humboldt University, Berlin, Germany, and was conducted according to the Declaration of Helsinki and largely following the International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice E6. Written informed consent was obtained from all patients before enrollment. Study reporting followed guidelines for reporting of observational studies.<sup>61,62</sup>

#### Data Analyses

All analyses were performed on all patients fulfilling the eligibility criteria for each respective analysis, using SPSS (SPSS, Inc, Chicago, Illinois; later PASW Statistics) versions 11-18, StatXact versions 5-9 (Cytel,

**Table 4** Documentation of Quality of Life

Recruitment period	Age, y	Outcome measure	Scores and scales	Reference no.
Jul 1998-Dec 2005	17-75	SF-36 Health Survey	Physical and Mental Component Summary scores, eight scales, Health Change item	57
Jul 1998-Mar 2001	8-16	KINDL 40-Item version	Total score; Psychic, Somatic, Social, and Function subscales	58
Apr 2001-Dec 2005	4-16	KINDL 24-item version	Total score; Physical Well-Being, Emotional Well-Being, Self-Esteem, Family, Friends, Everyday Functioning	59
Jul 1998-Mar 2001	1-7	KITA Quality of Life Questionnaire	Psychosoma, Daily Life	60

Abbreviations: KINDL, KINDL Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents; KITA, [German] Kindertagesstätte, daycare facility for children; SF-36, Short Form (36).

Inc, Cambridge, Massachusetts), and S-PLUS 8.0 (CANdiensten, Amsterdam).

**Sociodemographic Status.** Education levels were classified as low (Grade 1), intermediate (Grade 2), and high (Grade 3) according to the CASMIN educational classification.<sup>63</sup>

**Pre-post Analyses.** Pre-post assessments of clinical outcomes were subject to bivariate analysis using standard parametric and nonparametric methods: For paired continuous data, the *t*-test or the Wilcoxon Signed-Rank test was used; median differences with 95% confidence intervals were estimated according to Hodges and Lehmann. For bivariate binominal data, the McNemar test was used. All tests were two-tailed. For the diagnosis groups ADHD and asthma,<sup>29,30</sup> repeated measures analysis of variance also was performed. Pre-post effect sizes were calculated as standardized response mean and classified as minimal (<0.20), small (0.20-0.49), medium (0.50-0.79), and large ( $\geq 0.80$ ).<sup>64,65</sup>

In most cases,<sup>25,27-29,31,34-37,41</sup> the main analysis of clinical outcomes was performed on patients with evaluable data for each follow-up without replacement of missing values. Replacement of missing values with the last value carried forward was used in a number of sensitivity analyses<sup>27-29,31,34-37,41,45</sup> and as the main analysis in three cases.<sup>26,30,33</sup>

**Nested Prospective Comparative Non-randomized Study.** For the diagnosis group low back pain, a prospective nonrandomized comparative study was nested within the AMOS study.<sup>38</sup> In this study, AMOS patients with low back pain were compared to low back pain patients receiving conventional care. The patients in the two groups fulfilled identical eligibility criteria (see "Setting, participants, and therapy" above); AMOS patients were treated by AM physicians, while the patients in the control group were treated by physicians not using AM or other complementary therapies. Clinical outcomes and patient satisfaction were compared after 6 and 12 months. Clinical outcomes were compared using repeated measures analysis of variance, unadjusted and after adjustment for baseline score of the outcome, for gender, age, low back pain duration, and educational level (university entrance qualification).<sup>38</sup> Patient satisfaction was compared using Mann-Whitney U-test.<sup>38</sup>

### Systematic Outcome Comparison With Corresponding Cohorts in Other Studies.

For several other frequent diagnoses in AMOS, this study was the first outpatient study of AM therapy. It was therefore desirable to compare outcomes in AMOS to outcomes of other treatments for these diagnoses. Since only pre-post data were available in AMOS (apart from low back pain, see above), these comparisons would have to be of pre-post changes in patient cohorts derived from different studies. Although such comparisons cannot assess comparative effectiveness, they nevertheless yield information about the relative order of magnitude of treatment outcomes. Such comparisons are often presented in discussion sections as rudimentary narrative reviews; they are often limited to selected studies and often mix different outcomes and follow-up periods.

We devised a systematic extension and upgrading of this type of narrative review, combining the strengths of systematic, criteria-based literature selection and analysis with the descriptive assessment of treatment outcomes. A systematic review was conducted,<sup>44</sup> comprising the five largest AMOS diagnosis groups in adult patients: asthma, depression, low back pain, migraine, and neck pain. The five AMOS diagnosis groups were compared to all retrievable patient cohorts with corresponding diagnoses, outcome measures (SF-36 Health Survey<sup>66</sup>), and follow-up periods (3, 6, or 12 months) receiving other treatment.

Eligibility criteria for the comparison cohorts were

- prospective cohort of at least 20 evaluable adult patients (as in the AMOS diagnostic groups);
- at least 80% of the patients of the study or a defined subgroup thereof having one of the five diagnoses listed above (the AMOS diagnosis group anxiety disorders was not included in this review because of diagnostic heterogeneity with low sample sizes in relevant diagnostic subgroups: ICD-10 F41.1 generalized anxiety disorder [ $n = 28$ ], F41.0 panic disorder [ $n = 25$ ], F40 phobic anxiety disorder [ $n = 15$ ])<sup>28</sup>;
- patients starting any therapeutic intervention including treatment-as-usual; and
- results published in English or one of eight other listed languages.

In addition, for low back pain cohorts, the same



exclusion criteria as in the low back pain diagnosis group in AMOS applied (see above). Eligible publications were identified by systematic searches in 10 literature databases.<sup>44</sup>

For these comparisons, between-group effect sizes were calculated<sup>64</sup> and classified as pre-post analyses. Pre-post changes in an AMOS diagnosis group and in a corresponding cohort were defined to have the same order of magnitude if the between-group effect size was minimal to small (range  $-0.49$  to  $0.49$  standard deviations). The analyses of this review were descriptive without statistical hypothesis testing.<sup>44</sup>

**Predictors of Clinical Outcome.** Multiple linear regression analyses were performed to identify predictors of symptom score change from baseline after 6 and 12 months in adults<sup>42</sup> and in children.<sup>27</sup>

**Safety Analyses.** All suspected adverse reactions were classified as reported adverse reactions and subjected to descriptive analysis.<sup>25,26,28-33,35-37</sup> Suspected adverse reactions to AMPs as well as serious adverse events were also analyzed individually<sup>26,40</sup>; the causal relationship of these events medications and nonmedication therapies was classified according to predefined criteria as probable, possible, improbable, no relationship, or unable to evaluate. Events with a possible or probable causal relationship to AMPs were classified as confirmed adverse drug reactions.

**Health Costs.** Health costs were calculated by multiplying resource use with unit costs for the respective item. Resource use was documented by the patients, unit costs were calculated from average costs per item in Germany or from reimbursement fees regulated in healthcare benefit catalogues. For health costs, bootstrap means with bias-corrected and accelerated (BCa) bootstrap 95% confidence intervals were calculated, using 2000 replications per analysis.<sup>67</sup> All cost analyses<sup>25,39,43</sup> compared health costs in the pre-study year to costs in the first and (except in<sup>25</sup>) second study years. In one analysis, health costs were compared in adult AMOS patients treated for depression and patients treated for another disorder, with or without depressive symptoms, respectively, using generalized linear models.<sup>43</sup>

**Bias and Sensitivity Analyses. Selection bias.** Since AMOS had a long recruitment period, the study physicians were not able to screen and enroll all eligible patients. A patient selection on part of the physicians could bias results if physicians were able to predict therapy response and if they preferentially screened and enrolled such patients for whom they expected a particularly favorable outcome. It was hypothesized that if such selection bias occurred, the degree of patient selection (equal to the proportion of eligible vs enrolled patients) for each physician would be positively correlated with a favorable clinical outcome in his or her patients. The degree of patient selection was calculated from a survey of AMOS physicians of the number of eligible patients seen in the past 12 months. Correlations between the degree of patient selection and symptom score after 6 months<sup>42</sup> and 12 months<sup>31</sup>

were calculated using Spearman-Rho.

**Combined bias suppression.** Since AMOS was a single-arm cohort study (apart from the diagnosis of low back pain), the effect of the therapeutic interventions could not be separated from effects of other factors by comparison to a control group. For this reason a procedure for combined suppression of four relevant bias factors (nonrespondent bias, natural recovery, regression to the mean, and adjunctive therapies) was developed and used for a series of sensitivity analyses of clinical outcomes after 6 or 12 months. Nonrespondent bias was suppressed by replacing missing values with the baseline value carried forward. Regression to the mean was suppressed by replacing disease score at study enrolment with disease score 3 months before study enrolment. Bias from natural recovery was suppressed by restricting the analysis to patients with disease duration of at least 12 months. Bias from adjunctive therapies was suppressed by restricting the sample to patients not using diagnosis-related adjunctive therapies during the first 6 months after study enrolment. The four sensitivity analyses were then combined in an extreme scenario sensitivity analysis that was performed on all patients enrolled up to March 2001<sup>45</sup> and, with some modifications, in various subgroups.<sup>27-37,41</sup>

**Other sensitivity analyses.** The comparison of SF-36 outcomes in AMOS diagnosis groups and corresponding cohorts was reanalyzed, restricting the number of comparisons to increase comparability of study design, setting, therapy, and baseline score.<sup>44</sup> Predictors of clinical outcome were re-analyzed under altered conditions regarding the handling of missing values, the dependent variable, or the follow-up period, and were also re-analyzed in random subsamples.<sup>42</sup> Health costs were re-analyzed varying the assumptions about diagnostic criteria,<sup>39,43</sup> health resource use,<sup>25,43</sup> and costs per resource unit.<sup>25,43</sup>

## RESULTS

An overview of the 21 publications is given in Table 1. The publications can be accessed at [http://ifaemm.de/G10\\_AMOS.htm](http://ifaemm.de/G10_AMOS.htm). Main results are summarized in Table 2.

### Patient Recruitment and Follow-up

From July 1, 1998, to December 31, 2005, a total of 1631 patients aged 1 to 75 years were enrolled. Patients enrolled after December 31, 1998 ( $n = 1544$ ) had follow-up assessments beyond 12 months; this group includes 1510 patients with a disease duration of at least 30 days. The participating physicians ( $n = 151$ ) and therapists ( $n = 275$ ) resembled eligible but not participating AM physicians ( $n = 167$ ) and AM therapists ( $n = 911$ ) with respect to demographic characteristics, and the included patients resembled screened but not included patients regarding baseline characteristics.<sup>26</sup>

At the primary follow-up assessments of clinical outcomes after 6 or 12 months, the follow-up rate was 91% and 87%, respectively, in all patients<sup>26</sup> (range 77%-92% in

subgroups, Table 2). For each primary outcome assessment after 6 months<sup>25,27,28,30,33,41</sup> or 12 months<sup>29,31,34-38</sup> nonrespondent analyses were performed: Respondents and nonrespondents at the respective follow-ups did not differ significantly with regard to age, gender, disease duration, disease severity at baseline, and, if appropriate, diagnosis<sup>25,27-31,33-38,41</sup> (one exception in 73 nonrespondent analyses: significant difference for age in the rhythmical massage therapy group<sup>37</sup>). Corresponding nonrespondent analyses at the last follow-up after 24 months<sup>27,28,31,32,38</sup> or 48 months<sup>26,31,34,36</sup> were also mostly negative (five significant differences in 59 analyses). A telephone survey was performed on patients enrolled in the year 2005: the proportion of patients with clinical deterioration at 24-month follow-up was comparable in nonrespondents and respondents.<sup>32</sup>

**Baseline Characteristics**

The patients were recruited from 15 of 16 German Federal states.<sup>26</sup> Age groups were 1 to 19 years: 29.8% (n = 450/1510); 20 to 39 years: 25.4%; 40 to 59 years: 35.2%; and 60 to 75 years: 9.6%, with a median age of 37.0 years (interquartile range [IQR] 12.3-47.1 y, mean 33.8 ± 19.4 y). A total of 81.5% (n = 975/1074) of adults aged 17 to 75 years were women.<sup>26</sup>

Compared to the German population, adult patients had higher educational and occupational lev-

els and had a healthier lifestyle with regard to smoking, alcohol, and sports activities and were less overweight. The sociodemographic status of adults was similar to the population with regard to income and the proportion of adults living alone and less favorable for work disability pension and sick-leave (Table 5).<sup>26</sup>

In children,<sup>27</sup> the proportion of privately insured patients was comparable to that of the German population.<sup>76</sup>

Most frequent indications were mental disorders (ICD-10 F00-F99, 35.2%, n = 532/1510); musculoskeletal disorders (M00-M99, 15.4%); respiratory disorders (J00-J99, 9.9%); and neurological disorders (G00-G99, 7.2%).<sup>26</sup> The most frequent diagnosis groups are listed in Table 2. Disease duration at baseline was 1 month to 2 months in 4.4% (n = 67/1510) of patients; 3 to 5 months in 5.0%; 6 to 11 months in 8.5%; 1 to 4 years in 38.3%, and ≥5 years in 43.7%, with a median disease duration of 3.5 years (IQR 1.0-8.5 y, mean 6.6 ± 8.2 y).<sup>26</sup>

**Therapy**

At enrolment, 19.4% (n = 293/1510) of patients started AM therapy provided by the physician, while the remaining patients were referred to AM art therapy (18.2%), eurythmy therapy (52.6%), or rhythmical massage therapy (9.8%). Of the patients referred to art, eurythmy, or rhythmical massage therapy, 86.8% had the respective therapy, 0.5% did not have the therapy,

**Table 5** Sociodemographic Characteristics of Adult Patients (aged 17-75 y, n=1074)

Item	Subgroup	Patients		German Population	
		N	%	%	Reference no.
Education <sup>63</sup>	Low (Grade 1)	184	17.1	43	68, 69
	Intermediate (Grade 2)	530	49.3	43	
	High (Grade 3)	360	33.5	14	
Wage earners		39/1074	3.6	18	68
Unemployed during the past 12 mo	Economically active patients	37/618	6.0	10	68
Living alone		208/1069	19.5	21	68
Net family income <€900 per mo		160/871	18.4	16	68
Alcohol use daily (patients) vs almost daily (German population)	Male	12/198	6.1	28	70
	Female	19/875	2.2	11	
Regular smoking	Male	26/199	13.1	37	71
	Female	92/873	10.5	28	
Sports activity ≥1 hour weekly	Age 25-69 y	484/887	54.6	39	72
Body mass index <18.5 (low weight)	Male	7/196	3.6	1	68
	Female	61/863	7.1	4	
Body mass index ≥25 (overweight)	Male	64/196	32.7	56	68
	Female	219/863	25.4	39	
Permanent work disability pension		204/1072	19.0	3	73
Severe disability status		116/1072	10.8	12	74
Sick leave days in the last 12 months: mean ± standard deviation	Economically active patients	32.6 ± 67.3		17.0	75

Table reproduced from Hamre et al.<sup>26</sup>

and for 12.6%, the therapy documentation is incomplete. Median therapy duration was 119 days and median number of therapy sessions was 12 (IQR 84-190 d). AMPs were used by 71.7% (n = 1083/1510) of patients in months 0 to 24.<sup>26</sup>

Use of diagnosis-related non-AM adjunctive therapies in months 0-6 was analyzed in patients with a main diagnosis of mental, respiratory, or musculoskeletal diseases, headache syndromes, or menstruation-related gynecological disorders: 64.9% (n = 231/356) had no diagnosis-related adjunctive therapy.<sup>41</sup>

**Clinical Outcomes and Patient Satisfaction**

**Pre-post Analyses.** All primary outcome measures improved significantly from baseline to the primary follow-up assessment after 6 months,<sup>25-28,30,41</sup> 12 months,<sup>29,31,34-38</sup> or 48 months;<sup>26</sup> in the whole sample,<sup>25</sup> in adults and children, in all analyzed diagnosis groups,<sup>28-33</sup> and in all therapy modality groups<sup>34-37,41</sup> (Figure 1) ( $P < .001$  for all 24 pre-post comparisons). Standardized response mean effect sizes were large for 21 comparisons and medium for three comparisons (Table 6). Improvements were similar in patients not using conventional therapy for their main disorder.<sup>41</sup>

Quality-of-life scores (SF-36, KINDL, KITA, see Table 4) improved significantly from baseline to the primary follow-up assessments in the whole sample<sup>25</sup> and in most diagnosis<sup>28,31,32,38</sup> and therapy modality<sup>34-37,41</sup> groups (122 significant improvements in 138 pre-post analyses). Of the 16 pre-post analyses not showing significant improvements, five analyses had a sample size of <17 patients. All significant symptom and quality of life improvements were maintained at the last follow-up assessment after 12 months,<sup>41</sup> 24 months,<sup>27-30,32,33</sup> and 48 months,<sup>26,34-37</sup> respectively (one exception: KINDL total score in the asthma group, n = 12<sup>29</sup>).

At 6-month follow-up, the patients' mean rating of therapy outcome (0 = no help at all, 10 = helped very well) was 7.23 ± 2.39 points; patient satisfaction with therapy (0 = very dissatisfied, 10 = very satisfied) was 7.94


± 2.20 points.<sup>26</sup> In age, diagnosis, and therapy modality subgroups, the mean therapy outcome ratings ranged from 6.29 (ADHD symptoms<sup>30</sup>) to 7.54 (depression<sup>31</sup>) and therapy satisfaction ranged from 7.45 (ADHD symptoms<sup>30</sup>) to 8.23 (AM art therapy)<sup>35</sup> (Table 7).

**Nested Prospective Comparative Nonrandomized Study.** In a nested prospective nonrandomized comparative study, the AMOS diagnosis group low back pain was compared to patients starting conventional treatment for low back pain after 6 and 12 months.<sup>38</sup> In both groups analyzed together, back pain (Low Back Pain Rating Scale Pain Score<sup>56</sup>), back function (Hanover Functional Ability Questionnaire<sup>54</sup>), symptom score, and some SF-36 scales improved. Three SF-36 scales were significantly more improved in AMOS patients (Mental Health, General Health, and Vitality); other improvements did not differ significantly between the two groups. At 6-month follow-up, AMOS patients had significantly higher therapy outcome ratings ( $P = .009$ ) and showed a trend for higher patient satisfaction ( $P = .051$ ) than patients receiving conventional care (Table 7).<sup>38</sup>

**Systematic Outcome Comparison With Corresponding Cohorts in Other Studies.** In a systematic review, adult AMOS patients with asthma, depression, low back pain, migraine, and neck pain (n = 392 patients) were compared to other patient cohorts with corresponding diagnoses receiving other treatment.<sup>44</sup> A total of 63 publications fulfilled all eligibility criteria for the review (see Methods section). These publications reported one or more comparison cohorts with low back pain (n = 24 publications), depression (n = 13), migraine (n = 13), asthma (n = 11), and neck pain (n = 2), comprising 84 comparison cohorts with 16 167 patients. A total of 517 comparisons of 10 different SF-36 scales showed improvements largely of the same order of magnitude in AMOS subgroups and corresponding cohorts (minimal-to-small differences in 80% of the comparisons), with medium-to-large differences favoring AMOS and the corresponding cohorts in 14% and 7% of the comparisons, respectively (Figure 2). Sensitivity analyses had only small effects on the results.<sup>44</sup>

**Predictors of Clinical Outcomes.** In adults<sup>42</sup> and children,<sup>27</sup> improvements of symptom scores after 6 and 12 months were positively predicted by higher baseline symptom intensity and negatively predicted by longer disease duration. Baseline symptom severity was the strongest predictor, accounting for 25% and 17% of the variance after 6 months in adults and children, respectively (total models 32% and 23%, respectively). In adults, improvements were also positively predicted by better physical function, better general health, and (in most sensitivity analyses) higher education level and higher therapy goal at baseline.<sup>42</sup> The latter variable was not analyzed in children. In children, improvements were also negatively predicted by baseline disease score.<sup>27</sup>

**Bias Analyses. Patient selection.** It was estimated that the physicians enrolled 31% of all eligible



**Figure 1** Symptom Score stratified by therapy modality group. Range: 0 (not present) to 10 (worst possible). Patients aged 1-75 years, enrolled 1999-2001, n = 810. Data summarized from references 34-37.

**Table 6** Standardized Response Mean Effect Sizes of Primary Outcome Measures

Groups		Patient-reported Outcome Measures <sup>a</sup>	Month	SRM	N	Reference no.
All patients	Primary analysis	Symptom score	6	1.09	736	25
	Follow-up analysis	Symptom score	48	1.13	1510	26
Children		Symptom score	6	0.97	381	27
Diagnosis groups	Anxiety disorders	Anxiety severity	6	1.71	44	28
	Asthma	Average asthma severity	12	0.90	66	29
	ADHD symptoms	FBB-HKS total score [parent rating]	6	0.68	60	30
	Depression	CES-D	12	1.20	75	31
	Migraine	Average migraine severity	6	1.09	44	33
	Low back pain	HFAQ	24	0.59	46	32
	Low back pain	LBPRS	24	0.59	47	32
Therapy groups	Medical treatment					
	-Prolonged consultation with AM physician	Symptom score	12	1.05	184	34
	-AM products	Symptom score	6	1.01	559	41
	Art therapy	Symptom score	12	1.03	135	35
	Eurythmy therapy	Symptom score	12	1.04	336	36
	Rhythmical massage therapy	Symptom score	12	1.14	59	37
<b>Physician-reported outcome measures<sup>a</sup></b>						
All patients		Disease score	6	1.23	738	25
Children		Disease score	6	1.30	362	27
Diagnosis groups	Anxiety disorders	Anxiety severity	6	1.52	57	28
	Migraine	Average migraine severity	6	1.30	44	33
Therapy groups	Medical treatment					
	-Prolonged consultation with AM physician	Disease score	12	1.52	155	34
	-AM products	Disease score	6	1.35	583	41
	Art therapy	Disease score	12	1.76	97	35
	Eurythmy therapy	Disease score	12	1.34	237	36
	Rhythmical massage therapy	Disease score	12	1.45	56	37

<sup>a</sup> Outcome measures are described in Table 3.

Abbreviations: ADHD, attention deficit/hyperactivity disorder; AM, anthroposophic medicine; CES-D, Center for Epidemiological Studies Depression Scale; FBB-HKS: [German] Fremdbeurteilungsbogen für Hyperkinetische Störungen, a questionnaire of core ADHD symptoms; HFAQ, Hanover Functional Ability Questionnaire; LBPRS, Low Back Pain Rating Scale Pain score; SRM, standardized response mean effect size (minimal: <0.20, small: 0.20-0.49, medium: 0.50-0.79, large: ≥0.80).

patients.<sup>42</sup> The degree of patient selection for each physician did not correlate with symptom score improvements after 6 or 12 months.<sup>31,42</sup>

**Combined bias suppression.** In an analysis of all patients enrolled up to March 2001, four bias factors (nonrespondent bias, natural recovery, regression to the mean, and adjunctive therapies) could together explain a maximum of 37% of the 0- to 6-month improvement of disease score, with a residual improvement of 1.87 points (95% CI 1.69-2.06 points) (Figure 3).<sup>45</sup> Corresponding analyses of primary outcome measures were performed in children<sup>27</sup> and in the different diagnosis<sup>25,27-33</sup> and therapy modality groups;<sup>34-37,41</sup> suppressing one,<sup>32</sup> two,<sup>29,30,36</sup> three,<sup>27,28,34,35</sup> or four<sup>31,37,41</sup> bias factors. These analyses yielded similar results to the main bias analysis<sup>45</sup> (a maximum of 35% of the improvement explained in depression group<sup>31</sup>) or a lower percentage explained (range 0%-19% in other analyses).

**Safety**

The incidence of confirmed adverse reactions to AMPs was 3.0% (n = 20/662) of users; 2.2% (n = 21/949) of

the AMPs used; and 0.3% (n = 30/11487) of patient-months of AMP use. Confirmed adverse reactions of severe intensity occurred in 0.3% of AMP users while 1.5% had a confirmed reaction leading them to stop their AMP use.<sup>40</sup>

The incidence of reported adverse reactions to art, eurythmy, or rhythmical massage therapy was 2.0% (n = 21/1065) of therapy users for any reaction; 0.4% (n = 4) for reactions of severe intensity; and 0.3% (n = 3) for reactions leading patients to stop their therapy.<sup>26</sup>

No serious adverse reactions to any AMPs or AM therapies occurred.<sup>26</sup>

**Health Costs**

In a preliminary analysis without statistical hypothesis testing, total health costs were reduced by 4% from the pre-study year to the first study year.<sup>25</sup>

In a subsequent analysis of a larger sample size (Figure 4), costs in the first study year did not differ significantly from costs in the pre-study year, whereas in the second year, costs were significantly reduced by 13%.<sup>39</sup> Both these analyses<sup>25,39</sup> consisted of adults and children.

In an analysis of adult patients treated for depres-

Table 7 Patients' Rating of Therapy Outcome, Patient Satisfaction With Therapy

Groups		Therapy Outcome Rating			Satisfaction With Therapy			Reference no.
		Mean	SD	N <sup>a</sup>	Mean	SD	N <sup>a</sup>	
All patients		7.23	2.39	1275	7.94	2.20	1273	26
Age groups	Adults	7.33	2.33	556	8.01	2.16	558	77
	Children	7.12	2.56	370	7.87	2.27	371	27
Indications	Anxiety disorders	6.82	2.74	50	7.61	2.65	49	29
	Asthma	7.54	2.44	65	8.19	2.12	64	30
	Attention deficit/hyperactivity symptoms	6.29	2.70	52	7.45	2.12	51	31
	Depression	7.54	1.76	74	7.92	1.86	74	31
	Low back pain <sup>b</sup>							
	-Anthroposophic therapy (AMOS)	7.28	2.31	29	7.62	2.30	29	38
	-Conventional therapy (control group)	5.58	2.55	26	6.50	2.39	26	38
Therapy modalities	Migraine	7.33	2.42	33	7.72	2.05	32	33
	Medical treatment							
	-Prolonged consultations with anthroposophic physicians	7.21	2.64	182	7.81	2.45	182	34
	-Anthroposophic medicinal products	7.12	2.46	550	7.80	2.26	546	41
	Art therapy	7.52	1.95	132	8.23	1.79	133	35
	Eurythmy therapy	7.42	2.29	349	8.08	2.19	352	36
	Rhythmical massage therapy	7.50	2.34	62	8.18	2.08	62	37

Patients' ratings of therapy outcome (0 = no help at all, 10 = helped very much) and patient satisfaction with therapy (0 = very dissatisfied, 10 = very satisfied) at 6-month follow-up, analyzed in all patients and in different age, diagnosis, and therapy modality groups.

<sup>a</sup> Patients who returned the 6-month follow-up questionnaire with evaluable responses to the respective item.

<sup>b</sup> A nested prospective comparative nonrandomized study of patients with low back pain.<sup>38</sup>

sion, costs in the pre-study year were 102% and 63% higher than costs for patients treated for another disorder with and without depressive symptoms, respectively. Among the patients with depression, compared to the pre-study year, costs in the second study year were significantly decreased by 27%, while costs in the other two groups (patients with other disorders with or without depressive symptoms) showed little change.<sup>43</sup>

The cost reduction observed in these analyses was largely due to a reduction of inpatient hospitalization that could not be explained by secular trends during the study period.<sup>39</sup> Another possible explanation is frequent or long hospitalization early in the course of disease (diagnostic assessment, therapy initiation) followed by a normalization of hospitalization rates. A sensitivity analysis suggested that this factor could at maximum explain 37% of the hospitalization reduction.<sup>39</sup> Other sensitivity analyses<sup>25,39,43</sup> had only small effects on the results.

## DISCUSSION

### Main Findings


We have summarized methods and findings in all 21 peer-review publications from the AMOS study,<sup>25-45</sup> a 4-year prospective observational study of multimodal AM therapy for chronic disease in routine outpatient care. AMOS involved more than 400 therapy providers and more than 1600 patients with mental, musculoskeletal, respiratory, or neurological disorders or other chronic conditions. Following AM therapy (physician counseling, AMPs, art therapy, eurythmy therapy, rhythmical massage therapy), substantial and sustained improvements of disease symptoms and quality of life were observed.<sup>26</sup>

These improvements were found in adults<sup>25,42</sup> and children<sup>27</sup> and in all analyzed diagnosis<sup>25,27-33</sup> and therapy modality groups.<sup>34-37,41</sup> Quality of life improvements in adults were at least similar to improvements in patients receiving conventional care.<sup>38,44</sup> Health costs were not increased, although the patients were starting new AM therapy; in the second year, the costs were significantly decreased.<sup>39</sup> Adverse reactions to AM treatment were infrequent and mostly of mild-to-moderate intensity.<sup>34-37,40</sup> Patient satisfaction was high.<sup>26</sup>

### Significance of the Anthroposophic Medicine Outcomes Study

In terms of the numbers of participating therapy providers and patients, the scope of documentation, and the length of follow-up, AMOS is by far the largest clinical outcome study of AM to date. Nonetheless, one might ask why such a large number of publications has been forthcoming from this project. The main reason is the scarcity of data on clinical outcomes, costs, and safety of AM treatment for chronic noncancer conditions. AMOS includes the first clinical studies of anxiety disorders,<sup>28</sup> nonmedication AM therapy for migraine,<sup>33</sup> and rhythmical massage therapy for any indication,<sup>37</sup> as well as the first large studies of ADHD<sup>30</sup> and of eurythmy therapy.<sup>36</sup> In the field of primary care research, AMOS includes the first studies of depression,<sup>31</sup> low back pain,<sup>32,38</sup> AM medical treatment for chronic disease,<sup>34</sup> and AM art therapy for any indication,<sup>35</sup> as well as the first large study of AM treatment for children with chronic disease.<sup>27</sup> AMOS has yielded the first multivariate predictor analyses of long-term outcome following AM treat-





**Figure 2** Outcome comparisons stratified by diagnoses.

Differences between pre-post improvements of Anthroposophic Medicine Outcomes Study (AMOS) cohorts and improvements of corresponding cohorts for all SF-36 scales and summary measures, expressed in effect sizes and ordered in increasing magnitude: for all diagnoses and for individual diagnoses ( $n = 517$  comparisons in total). Positive effect sizes indicate larger pre-post improvement in AMOS cohort than in corresponding cohort.

Figure reproduced from Hamre et al.<sup>44</sup>


ment for chronic noncancer indications in adults<sup>27</sup> and children,<sup>27</sup> the first detailed safety analysis of AMPs within a large prospective cohort study,<sup>40</sup> and the first detailed economic analysis of AM treatment.<sup>39</sup> These comparisons refer to published and unpublished studies on AM.<sup>78</sup> A comparison restricted to peer-review publications would underline the pioneer position of AMOS even more.

Apart from its significance for the evaluation of AM treatment, AMOS has also fostered two methodological innovations for the analysis of single-arm therapy studies (combined bias suppression<sup>45</sup> and systematic outcome comparison with corresponding cohorts in other studies<sup>44</sup>) and the first depression cost analysis worldwide comparing primary care patients treated for depression vs depressed patients treated for another disorder vs non-depressed patients.<sup>43</sup>

### Strengths and Limitations

Strengths of AMOS and the body of AMOS publications include a naturalistic real-world therapy setting; a large sample size; a long follow-up period; the combination of generic and disease-specific outcome measures; a high representativeness of the participating physicians, therapists, and patients; detailed cost and safety analyses; and the widespread use of sensitivity analyses.

The AMOS study had an observational single-arm design. In addition, a concurrent nonrandomized control group was available for the diagnosis group low back pain,<sup>38</sup> but the validity of this comparison is limited by a high nonrespondent rate of 42% in the control group. Furthermore, a systematic comparative review was conducted in order to assess the order magnitude of the improvements in AMOS relative to improvements in other therapy studies. Comparative



**Figure 3** Disease score without and with combined bias suppression. Patients aged 1-75 years, enrolled 1999-2001 with disease score available at baseline, n = 887. Figure reproduced from Hamre et al.<sup>45</sup>

samples were identified through systematic reviews for five common AMOS diagnoses. Outcomes were then evaluated to assess similarities and differences between AM treatment outcomes and those for a variety of other treatment strategies. These nonconcurrent comparisons were descriptive and limited to comparative order of magnitude.<sup>44</sup>


To further compensate for the limitations of the pre-post design, a systematic procedure to assess the potential impact of four possible causes of pre-post improvements, apart from AM therapy (nonrespondent bias, natural recovery, regression to the mean, adjunctive therapies) on clinical outcomes was developed and used in AMOS. This combined bias suppression procedure is novel and needs to be further evaluated in future studies.<sup>45</sup>

Another issue is the possibility of selection bias from physicians' expectations of the patients' future therapy response (see Methods for details). Extensive analyses suggest that if such a patient selection did occur, this selection did not affect clinical outcomes.<sup>31,42</sup>

The integration of different diagnosis-specific documentation modules into one research project in routine outpatient care necessitated some compromises: eg, there were no data on airway caliber in asthma patients<sup>29</sup> and no structured psychiatric interviews for diagnostic assessment of patients with mental disorders.<sup>28,30,31</sup>

### Comparison to Other Studies of Multimodal Anthroposophic Treatment

Multimodal AM treatment (including AMPs and nonmedication AM therapies) for chronic noncancer indications has been investigated in other studies with various indications: anorexia nervosa,<sup>79-81</sup> asthma,<sup>82</sup> epilepsy,<sup>83</sup> hepatitis C,<sup>84,85</sup> inflammatory rheumatic disorders,<sup>85</sup> intervertebral disc disease,<sup>86</sup> and rehabilitation after stroke.<sup>87</sup> These studies were performed in inpatient hospitals<sup>79-81,84,87,88</sup> or specialized outpatient clinics<sup>82,83,85,86</sup> and had, like AMOS, an observational



**Figure 4** Health costs.

Patients aged 1-75 years, enrolled 1999-2001 with available data for ≥3 of 5 follow-ups, n = 717. Figure reproduced from Hamre et al.<sup>39</sup>

Abbreviation: AM, anthroposophic medicine.

design. All studies showed benefit from AM treatment.<sup>78</sup> The AMOS study, in predominantly primary care settings, showed substantial and sustained improvements in symptoms and quality of life<sup>25</sup> in accordance with these studies from specialized settings.

### Implications for Practice

Within the limits of an observational, largely pre-post design, the AMOS study suggests that AM therapies can be useful in the long-term care of patients with chronic noncancer disease.

### Implications for Research

The analysis and publication strategy for AMOS incorporates two features proposed for the evaluation of complementary or integrative therapy systems. The first feature is a sequential approach,<sup>89,90</sup> starting with the whole therapy system (use, safety, outcomes, perceived benefit),<sup>25-27,42,45</sup> addressing comparative effectiveness,<sup>38,44</sup> and then proceeding to an evaluation of the major system components.<sup>34-37,41</sup> The second feature is using a mix of different research methods to build an information synthesis,<sup>90</sup> including pre-post observational studies,<sup>25-37,41,45</sup> comparative observational studies,<sup>38,43</sup> systematic reviews,<sup>44</sup> economic analyses,<sup>39,43</sup> and safety analyses of individual patient data.<sup>40</sup> Notably, an evaluation strategy incorporating such features<sup>89,90</sup> will usually comprise a series of research projects, while AMOS was one single project.

Future studies on AM treatment for chronic disease will probably not attempt to replicate AMOS by including all age groups and all chronic indications but

rather focus on selected diagnoses in adults or children. However, AMOS has shown that further investigations on AM therapy for the most frequent diagnosis groups in this project may be worthwhile.

There is scope for experimental and observational studies, further whole-system evaluations, and evaluations of individual therapy components, also including physiological effects of AM treatment.<sup>91-94</sup> In addition, there is scope for qualitative studies exploring the experiences of patients undergoing AM treatment.

## CONCLUSIONS

In the AMOS study, multimodal AM treatment for outpatients with chronic disease was safe and was associated with clinically relevant and sustained improvements in symptoms and in quality of life, as well as reduced costs.

## REFERENCES

- Evans M, Rodger I. *Healing for body, soul and spirit: an introduction to anthroposophical medicine*. Edinburgh, Scotland: Floris Books; 2000.
- Steiner R, Wegman I. *Fundamentals of therapy* [First edition 1925]. Whitefish, MT: Kessinger Legacy Reprints; 2010.
- Lindenberg C. Rudolf Steiner—a biography. Great Barrington, MA: Steiner Books; 2012.
- Kienle GS, Albonico HU, Baars E, Hamre HJ, Zimmermann P, Kiene H. Anthroposophic medicine—an integrative medicine system originating in Europe. *Global Adv Health Med*. 2013;2(6):20-31.
- Heusser P. *Anthroposophische Medizin und Wissenschaft. Beiträge zu einer integrativen medizinischen Anthropologie*. [Anthroposophic medicine and science. Towards an integrative medical anthropology]. Stuttgart, Germany: Schattauer-Verlag; 2010.
- Zimmermann P, Winkler M, Arendt A, et al. Facts and figures on anthroposophic medicine worldwide. Brussels, International Federation of Anthroposophic Medical Associations. Last update: 2012. [http://www.ivaa.info/fileadmin/editor/file/Facts\\_and\\_Figures\\_AM\\_Worldwide/July2012\\_Final\\_Public\\_Light.pdf](http://www.ivaa.info/fileadmin/editor/file/Facts_and_Figures_AM_Worldwide/July2012_Final_Public_Light.pdf). Accessed November 13, 2013.
- Anthroposophic Pharmaceutical Codex APC, 3rd ed. Dornach, Switzerland: The International Association of Anthroposophic Pharmacists IAAP; 2013.
- Bornhöft G, Matthiessen PF. *Homeopathy in healthcare: effectiveness, appropriateness, safety, costs*. Berlin: Springer-Verlag; 2011.
- Basic information on the working principles of anthroposophic pharmacy. 2nd ed. Dornach, Switzerland: The International Association of Anthroposophic Pharmacists IAAP; 2005. <http://www.iaap.org.uk/downloads/principles.pdf>. Accessed November 13, 2013.
- Hauschka-Stavenhagen M. *Fundamentals of artistic therapy, based on spiritual science*. Spring Valley, NY: Mercury Press; 2005.
- Collot d'Herbois L. *Light, darkness and color in painting therapy*. Dornach: Goetheanum Press; 1993.
- Denjean-von Stryk B, von Bonin D, Krampe M. *Anthroposophical therapeutic speech*. Edinburgh, Scotland: Floris Books; 2003.
- Felber R, Reinhold S, Stückert A. *Musiktherapie und Gesang* [Music therapy and singing]. Stuttgart, Germany: Verlag Freies Geistesleben & Urachhaus; 2000.
- Golombek E. *Plastisch-Therapeutisches Gestalten* [Therapeutic sculpture]. Stuttgart, Germany: Verlag Freies Geistesleben & Urachhaus; 2000.
- Mees-Christeller E, Denzinger I, Altmaier M et al. *Therapeutisches Zeichnen und Malen* [Therapeutic drawing and painting]. Stuttgart, Germany: Verlag Freies Geistesleben & Urachhaus; 2000.
- Majorek M, Tüchelmann T, Heusser P. Therapeutic eurythmy-movement therapy for children with attention deficit hyperactivity disorder (ADHD): a pilot study. *Complement Ther Nurs Midwifery*. 2004;10(1):46-53.
- Kirchner-Bockholt M. *Foundations of curative eurythmy*. 2nd ed. Edinburgh, Scotland: Floris Books; 2004.
- Hauschka-Stavenhagen M. *Rhythmical massage as indicated by Dr. Ita Wegman*. Spring Valley, NY: Mercury Press; 1990.
- Ritchie J, Wilkinson J, Gantley M, et al. *A model of integrated primary care: anthroposophic medicine*. London: Department of General Practice and Primary Care, St Bartholomew's and the Royal London School of Medicine, Queen Mary, University of London; 2001.
- Guidelines for good professional practice in anthroposophic medicine. International Federation of Anthroposophic Medical Associations. Last update: 2003. <http://www.ivaa.info/anthroposophic-medicine/quality-control-in-am/guidelines-for-good-professional-practice-in-anthroposophic-medicine/>. Accessed November 20, 2013.
- Pütz H. *Leitlinie zur Behandlung mit Anthroposophischer Kunsttherapie (BVAKT)® für die Fachbereiche Malerei, Musik, Plastik, Sprachgestaltung* [Guideline for treatment with anthroposophic art therapy with the therapy modalities painting, music, clay, speech]. Filderstadt, Germany: Berufsverband für Anthroposophische Kunsttherapie e. V. [Association for Anthroposophic Art Therapy in Germany]; 2008.
- Eurythmy therapy guideline. Filderstadt, Germany: Berufsverband Heileurythmie e.V. (Eurythmy Therapy Association); 2004.
- Vademecum of anthroposophic medicines. First English ed. Filderstadt, Germany: Medical Section of the School of Spiritual Science; International Federation of Anthroposophic Medical Associations (IVAA); Association of Anthroposophic Physicians in Germany (GAÄD); 2009.
- Complementary and alternative medicines (CAM) and traditional medicinal products (TMP). Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). Last update: 2012. [http://www.bfarm.de/EN/drugs/2\\_Authorisation/types/pts/pts-node-en.html](http://www.bfarm.de/EN/drugs/2_Authorisation/types/pts/pts-node-en.html). Accessed November 20, 2013.
- Hamre HJ, Becker-Witt C, Glockmann A, et al. Anthroposophic therapies in chronic disease: The Anthroposophic Medicine Outcomes Study (AMOS). *Eur J Med Res* 2004;9(7):351-60.
- Hamre HJ, Kiene H, Glockmann A, et al. Long-term outcomes of anthroposophic treatment for chronic disease: a four-year follow-up analysis of 1510 patients from a prospective observational study in routine outpatient settings. *BMC Res Notes*. 2013;6(1):269.
- Hamre HJ, Witt CM, Kienle GS, et al. Anthroposophic therapy for children with chronic disease: a two-year prospective cohort study in routine outpatient settings. *BMC Pediatr*. 2009 Jun 19;9:39.
- Hamre HJ, Witt CM, Kienle GS, et al. Anthroposophic therapy for anxiety disorders: a two-year prospective cohort study in routine outpatient settings. *Clin Med Psychiatry* 2009;2:17-31.
- Hamre HJ, Witt CM, Kienle GS, et al. Anthroposophic therapy for asthma: a two-year prospective cohort study in routine outpatient settings. *J Asthma Allergy*. 2009 Nov 24; 2:111-28.
- Hamre HJ, Witt CM, Kienle GS, et al. Anthroposophic therapy for children with attention deficit hyperactivity: a two-year prospective study in outpatients. *Int J Gen Med*. 2010;3:239-53.
- Hamre HJ, Witt CM, Glockmann A, et al. Anthroposophic therapy for chronic depression: a four-year prospective cohort study. *BMC Psychiatry*. 2006 Dec 15;6:57.
- Hamre HJ, Witt CM, Kienle GS, et al. Long-term outcomes of anthroposophic therapy for chronic low back pain: a two-year follow-up analysis. *J Pain Res*. 2009;2:75-85.
- Hamre HJ, Witt CM, Kienle GS, et al. Anthroposophic therapy for migraine: a two-year prospective cohort study in routine outpatient settings. *Open Neurol J*. 2010;4:100-10.
- Hamre HJ, Witt CM, Glockmann A, et al. Anthroposophic medical therapy in chronic disease: a four-year prospective cohort study. *BMC Complement Altern Med*. 2007;7:10.
- Hamre HJ, Witt CM, Glockmann A, et al. Anthroposophic art therapy in chronic disease: a four-year prospective cohort study. *Explore (NY)*. 2007;3(4):365-71.
- Hamre HJ, Witt CM, Glockmann A, et al. Eurythmy therapy in chronic disease: a four-year prospective cohort study. *BMC Public Health*. 2007 Apr 23;7:61.
- Hamre HJ, Witt CM, Glockmann A, et al. Rhythmical massage therapy in chronic disease: a 4-year prospective cohort study. *J Altern Complement Med*. 2007;13(6):635-42.
- Hamre HJ, Witt CM, Glockmann A, et al. Anthroposophic vs. conventional therapy for chronic low back pain: a prospective comparative study. *Eur J Med Res*. 2007;12(7):302-10.
- Hamre HJ, Witt CM, Glockmann A, et al. Health costs in anthroposophic therapy users: a two-year prospective cohort study. *BMC Health Serv Res* 2006;6:65.
- Hamre HJ, Witt CM, Glockmann A, et al. Use and safety of anthroposophic medications in chronic disease: a 2-year prospective analysis. *Drug Saf*. 2006;29(12):1173-89.
- Hamre HJ, Witt CM, Glockmann A, et al. Outcome of anthroposophic medication therapy in chronic disease: A 12-month prospective cohort study. *Drug Des Devel Ther*. 2008;2:25-37.
- Hamre HJ, Witt CM, Kienle GS, et al. Predictors of outcome after 6 and 12 months following anthroposophic therapy for adult outpatients with chronic disease: a secondary analysis from a prospective observational study. *BMC Res Notes*. 2010;3:218.
- Hamre HJ, Witt CM, Glockmann A, et al. Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings. *Eur J Health Econ*. 2010;11(1):77-94.
- Hamre HJ, Glockmann A, Tröger W, et al. Assessing the order of magnitude of outcomes in single-arm cohorts through systematic comparison with corresponding cohorts: an example from the AMOS study. *BMC Med Res Methodol*. 2008;8(11).
- Hamre HJ, Glockmann A, Kienle GS, et al. Combined bias suppression in single-arm therapy studies. *J Eval Clin Pract*. 2008;14(5):923-9.

**Acknowledgments**  
Our special thanks go to the study physicians, therapists, and patients for participating.

46. Schürholz J, Dilschmann A. Kooperationsvereinbarung über die ärztliche Versorgung mit Anthroposophischer Medizin [Cooperation agreement on a healthcare provision with anthroposophic medicine]. Filderstadt, Hamburg: Gesellschaft Anthroposophischer Ärzte in Deutschland e.V.; Innungskrankenkasse Hamburg; 1997.
47. Diagnostic criteria from the DSM-IV. Washington, DC: American Psychiatric Association; 1994.
48. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, neuralgias, and facial pain. *Cephalalgia*. 1988;8 (Suppl 7):1-96.
49. Boon H, MacPherson H, Fleishman S, et al. Evaluating complex healthcare systems: a critique of four approaches. *Evid Based Complement Alternat Med*. 2007;4(3):279-285.
50. Downie WW, Leatham PA, Rhind VM, et al. Studies with pain rating scales. *Ann Rheum Dis*. 1978;37(4):378-381.
51. Döpfner M, Görtz-Dorten A, Lehmkuhl G. DISYPS-II. Diagnostik-System für psychische Störungen nach ICD-10 und DSM-IV für Kinder und Jugendliche - II. Manual. [DISYPS-II. Diagnostic assessment system for mental disorders in children and adolescents according to ICD-10 and DSM-IV, 2nd ed. manual]. Bern, Germany: Verlag Hans Huber; 2008.
52. Döpfner M, Lehmkuhl G. DISYPS-KJ. Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV. Manual. [DISYPS-KJ. Diagnostic assessment system for mental disorders in children and adolescents according to ICD-10 and DSM-IV manual]. Bern, Germany: Verlag Hans Huber; 2000.
53. Hautzinger M, Bailer M. ADS, Allgemeine Depressions Skala. [Center for Epidemiological Studies Depression Scale, German version.] Weinheim: Beltz Test; 1993.
54. Kohlmann T, Raspe H. Der Funktionsfragebogen Hannover zur alltäglichen Diagnostik der Funktionsbeeinträchtigung durch Rückenschmerzen (FFbH-R). [Hannover Functional Questionnaire in ambulatory diagnosis of functional disability caused by backache]. Rehabilitation (Stuttg). 1996;35(1):I-VIII.
55. Michel A, Kohlmann T, Raspe H. The association between clinical findings on physical examination and self-reported severity in back pain. Results of a population-based study. *Spine*. 1997;22(3):296-303.
56. Manniche C, Asmussen K, Lauritsen B, et al. Low Back Pain Rating Scale: validation of a tool for assessment of low back pain. *Pain*. 1994;57(3):317-326.
57. Bullinger M, Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand. Handanweisung. [SF-36 Health Survey, German Version: Handbook]. Göttingen, Germany: Hogrefe-Verlag; 1998.
58. Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. *Qual Life Res*. 1998;7(5):399-407.
59. Ravens-Sieberer U, Bullinger M. KINDL® English. Questionnaire for measuring health-related quality of life in children and adolescents. Revised version. Berlin: Robert Koch Institute; 2000.
60. Wittorf M. KITA - Fragebogen zur Erfassung der gesundheitsbezogenen Lebensqualität von Kleinkindern zwischen 1 und 6 Jahren. Dissertation. [KITA questionnaire for health-related quality of life in children aged 1-6 years. Dissertation]. Berlin: Institute of Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center; 2001.
61. Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. *Am J Public Health*. 2004;94(3):361-6.
62. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335(7624):806-8.
63. Brauns H, Steinmann H. Educational reform in France, West-Germany and the United Kingdom: updating the CASMIN educational classification. Mannheim: Mannheim Centre for European Social Research (MZES); 1997.
64. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
65. McDowell I. Measuring health. A guide to rating scales and questionnaires. 3rd ed. Oxford: Oxford University Press; 2006.
66. Ware JE, Sherbourne CD. A 36-item short form health survey (SF-36): Results from the Medical Outcomes Study. *Med Care*. 1992;30:473-83.
67. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. *Stat Med*. 2000;19(9):1141-64.
68. Federal Statistical Office. Statistical yearbook for the Federal Republic of Germany. Stuttgart, Germany: Metzler-Poeschel Verlag; 2001.
69. Bundesgesundheitsurvey 1998. Public Use File [Federal Health Survey 1998. Public Use File]. Berlin: Robert Koch Institute; 2000.
70. Hoffmeister H, Schelp FP, Mensink GB, et al. The relationship between alcohol consumption, health indicators and mortality in the German population. *Int J Epidemiol*. 1999;28(6):1066-72.
71. Junge B, Nagel M. Das Rauchverhalten in Deutschland. [Smoking behavior in Germany]. *Gesundheitswesen*. 1999;61(Sonderheft 2):S121-5.
72. Breckenkamp J, Laaser U, Danell T. Freizeitinteressen und subjektive Gesundheit. [Hobbies and Subjective Health]. Wiesbaden, Germany: Federal Institute for Population research at the Federal Statistical Office; 2001. <http://www.bib-demographie.de/publikat/materialien/Heftr02b.pdf>
73. VDR Statistik Rentenbestand am 31. Dezember 2000. [VDR-Statistics of Pensioners on December 31, 2000]. Berlin: Association of German Pension Insurance Companies; 2005.
74. Bergmann E, Ellert U. Sehhilfen, Hörhilfen und Schwerbehinderung. [Seeing aids, hearing aids, and disabilities]. *Bundesgesundheitsblatt*. 2000;43(6):432.
75. Arbeitsunfähigkeits-, Krankengeld- und Krankenhausfälle und -tage nach der GKV-Statistik KG2 1996 bis 2002. [Number of cases and days with sick leave and with inpatient hospitalization, according to the statistics of the Statutory Health Insurance KG2, 1996 to 2002]. Bonn, Germany: Ministry of Health and Social Welfare; 2003.
76. Die private Krankenversicherung 2002/2003. Zahlenbericht. [Financial report for private healthcare insurance 2002/2003]. Cologne: Association of German Private Healthcare Insurers; 2003.
77. Hamre HJ, Glockmann A, Kienle GS, et al. Abschlussbericht: Wissenschaftliche Begleitung des Modellprojekts Anthroposophische Medizin der Innungskrankenkasse Hamburg. [Report: Scientific evaluation of the Model Project Anthroposophic Medicine of the Innungskrankenkasse Hamburg.] Freiburg, Germany: Institute for Applied Epistemology and Medical Methodology; 2005.
78. Kienle GS, Kiene H, Albonico HU. Anthroposophic medicine: effectiveness, utility, costs, safety. Stuttgart, New York: Schattauer Verlag; 2006.
79. Knol MGP. Die Behandlung von Kindern mit Asthma und/oder Ekzem. Forschungs-jahr "Anthroposophische Kinderheilkunde" am Gemeinschaftskrankenhaus Herdecke 1. August 1988 bis 01. August 1989. [Treatment of children with asthma and/or eczema. Research year "anthroposophic pediatrics" at the Herdecke Community Hospital, August 1, 1988 to August 1, 1989.] Herdecke: Herdecke Community Hospital; 1989.
80. Kienle GS, Kiene H, Albonico HU. [Catamnesic survey of patients with anorexia nervosa: Treatment outcome and social rehabilitation. Dissertation] In: Anthroposophic medicine: effectiveness, utility, costs, safety. Stuttgart, New York: Schattauer Verlag; 2006. Schäfer 1997:96-100.
81. Schmitz S. Der anthroposophische Ansatz zur Therapie von Magersucht - Eine alternative Behandlungsmethode und ihre Erfolge. Dissertation. [The anthroposophic approach to anorexia therapy—outcome of an alternative treatment method. Dissertation]. Hamburg: University of Hamburg; 1989.
82. Ecker D, Uithoven MA, van Dijk HA. Anthroposophische Asthmatherapie im Vergleich. Ersetzt sie das inhalative Corticoid? [Anthroposophical asthma therapy: a comparison. Is it as good as inhalative corticosteroids?]. *Schweiz Z Ganzheitsmedizin*. 2001;13(6):326-34.
83. Madeyn R. Gesichtspunkte zur Epilepsie und deren Behandlungsmöglichkeit bei Kindern. [Treatment of epilepsy in children]. *Der Merkurstab*. 1990;43(6):369-84.
84. Martini I. Anwendungsbeobachtungen mit Iscucin-Quercus bei ehemals i.v.-Drogenabhängigen mit chronischer Hepatitis C des Genotyp 1 in SYNANON Schmerwitz. [Observational study of Iscucin-Quercus for chronic hepatitis genotype 1 in former drug addicts in SYNANON Schmerwitz]. *Der Merkurstab*. 1999;52 (Sonderheft Hepatitis):42-53.
85. Matthes H, Matthes B, Biesenthal S. Survey of unconventionally hepatitis C therapy with an aqueous mistletoe extract and lycopersicon esculentum. *Gastroenterology*. 2000;118(5):2000.
86. Simon L, Schietzel T, Gärtner C, et al. Ein anthroposophisches Therapiekonzept für entzündlich-rheumatische Erkrankungen. Ergebnisse einer zweijährigen Pilotstudie. [An anthroposophic therapy concept for inflammatory rheumatoid disorders. Results of a two-year pilot study]. *Forsch Komplementärmed*. 1997;4:17-27.
87. Kienle GS, Kiene H, Albonico HU. Rivoir 2001 [Retrospective comparison of anthroposophic versus conventional treatment of intervertebral disc disease]. In: Anthroposophic medicine: effectiveness, utility, costs, safety. Stuttgart, New York: Schattauer Verlag; 2006:140-1.
88. Scheel-Sailer A. Art therapies in the primary treatment of paraplegic patients. a qualitative study. In: Aldridge D, editor. Music therapy and neurological rehabilitation. Performing health. London: Jessica Kingsley Publishers, 2005; 231-60.
89. Fønnebo V, Grimsgaard S, Walach H, et al. Researching complementary and alternative treatments—the gatekeepers are not at home. *BMC Med Res Methodol*. 2007;7:7.
90. Kienle GS, Albonico HU, Fischer L, et al. Complementary therapy systems and their integrative evaluation. *Explore (NY)*. 2011;7(3):175-87.
91. Wachter R, Brenneisen R, Hamburger M, et al. Leaf press juice from *Bryophyllum pinnatum* (Lamarck) Oken induces myometrial relaxation. *Phytomedicine*. 2011;19(1):74-82.
92. Gründemann C, Garcia-Kaufner M, Sauer B et al. Traditionally used *Veronica officinalis* inhibits proinflammatory mediators via the NF-kappaB signalling pathway in a human lung cell line. *J Ethnopharmacol*. 2013;145(1):118-26.
93. Seifert G, Kanitz JL, Pretzer K, et al. Improvement of circadian rhythm of heart rate variability by eurythmy therapy training. *Evid Based Complement Alternat Med*. 2013;2013:564340.
94. Wälchli C, Saltzwedel G, Krüerke D, et al. Physiologic effects of rhythmical massage: a prospective exploratory cohort study. *J Altern Complement Med*. 2013 May 23. [Epub ahead of print]